SOMA

TB-500 (Thymosin Beta-4): Tissue Recovery Research Guide

Synthetic analogue of the ubiquitous 43 amino acid Thymosin Beta-4 protein — studied for actin regulation, angiogenesis, and accelerated tissue recovery in preclinical models.

SEO Target tb 500 peptide
Amino Acids 43 (full Tβ4)
Market Avg $92
Sub-Line SOMA
Research Updated April 2026

What Is TB-500?

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in angiogenesis, muscle regeneration, wound repair, and cardiac protection in preclinical research.

TB-500 is a synthetic peptide analogue corresponding to the actin-binding active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43 amino acid protein expressed ubiquitously in mammalian cells. Thymosin Beta-4 was originally isolated from thymic tissue during a systematic investigation of thymic peptide fractions in the 1960s and 1970s. The full-length protein is among the most abundant intracellular peptides in many cell types, where it plays an indispensable role in regulating the dynamics of the actin cytoskeleton — the fundamental scaffold governing cell shape, motility, and division.

The "TB-500" designation is commonly used in research settings to refer to the synthetic version of the LKKTETQ heptapeptide sequence corresponding to the actin-binding domain (residues 17–23) of the full Thymosin Beta-4 molecule. Research has demonstrated that this fragment retains substantial biological activity comparable to the complete protein in many in vitro and animal model assays. This has made TB-500 a cost-effective and accessible tool for preclinical research applications compared to working with the full recombinant protein.

The scientific literature on Thymosin Beta-4 and its analogues is extensive, spanning cardiac repair, ocular wound healing, central nervous system protection, skin wound healing, and musculoskeletal tissue recovery. Studies by Dr. Hynda Kleinman at the NIH and collaborators have been particularly significant in establishing the mechanistic basis for Tβ4's pro-angiogenic and anti-inflammatory activities. TB-500 research compounds from Rainbow Peptide are provided exclusively for licensed research use. They are not approved for or intended for human administration under any circumstances.

Mechanism of Action

TB-500 / Thymosin Beta-4 acts primarily by sequestering G-actin to promote cell migration, upregulating the PI3K/Akt survival pathway, stimulating VEGF-mediated angiogenesis, and reducing inflammatory cytokines at injury sites.

  • G-Actin Sequestration and Cytoskeletal Regulation

    TB-500's primary biochemical role is sequestration of monomeric globular actin (G-actin). By binding G-actin with high affinity, TB-500 modulates the equilibrium between G-actin and filamentous F-actin, influencing cytoskeletal dynamics critical for cell migration. This mechanism is particularly relevant to wound-edge fibroblast and keratinocyte mobilisation in healing tissue research models.

  • Anti-Inflammatory Cytokine Downregulation

    Research demonstrates TB-500 / Tβ4 suppresses inflammatory mediators including TNF-α, IL-1β, and IL-6 in macrophage and cardiac fibroblast models. The anti-inflammatory effect is proposed to involve NF-κB pathway modulation, reducing leukocyte infiltration scores in acute injury animal models — a profile distinct from steroid-based anti-inflammatory compounds.

  • Angiogenesis via Integrin Signalling

    Tβ4 interacts with integrin-linked kinase (ILK), activating downstream AKT and VEGF signalling. In corneal and dermal wound models, this pathway promotes endothelial cell sprouting and microvascular network formation. The pro-angiogenic effect appears dependent on an intact ILK interaction domain — a mechanistic target for ongoing molecular research.

  • Cardiac Progenitor Cell Activation

    Post-myocardial infarction studies in rodent models have demonstrated Tβ4 pretreatment activates cardiac progenitor cells and reduces scar size. The proposed mechanism involves epicardial EMT (epithelial-mesenchymal transition) induction and activation of cardiomyocyte survival pathways. This cardiac research dimension represents one of the more advanced translational research areas for this compound class.

  • Stem Cell Chemoattraction

    TB-500 / Tβ4 has demonstrated chemotactic activity in stem cell migration assays, attracting mesenchymal stem cells (MSCs) toward wound sites in vitro. This chemoattraction is proposed to amplify endogenous repair responses by recruiting repair-competent progenitor populations to sites of tissue damage — an area of active investigation in regenerative medicine research.

Key Research Findings

2004

Accelerated Wound Healing in Dermal Models

Kleinman et al. demonstrated in full-thickness dermal wound models that topical Tβ4 application significantly accelerated wound closure rates compared to vehicle controls. Histological analysis showed increased granulation tissue formation, higher microvessel density, and earlier keratinocyte migration to wound margins. The authors identified the LKKTETQ actin-binding sequence as the active effector domain — the region corresponding to TB-500.

Kleinman HK et al. — Ann N Y Acad Sci, 2004
2010

Cardiac Protection and Reduced Infarct Size

Bock-Marquette et al. investigated Tβ4 in a mouse model of myocardial infarction. Animals receiving Tβ4 showed statistically significant reductions in infarct size, improved ejection fraction, and enhanced cardiomyocyte survival at both 1 and 4 weeks post-infarct. The proposed mechanism involved AKT phosphorylation and downstream anti-apoptotic signalling — establishing a basis for continued cardiac biology research.

Bock-Marquette I et al. — Nature, 2010
2014

Tendon and Ligament Recovery Studies

Research in rodent Achilles tendon injury models found TB-500 administration correlated with significantly faster tendon strength recovery and improved collagen organisation scores by 3 weeks post-surgery. Immunohistochemical staining showed elevated type I collagen and tenomodulin expression in TB-500-treated tendons, with reduced CD68+ macrophage infiltration suggesting a more controlled inflammatory resolution phase.

Xu Y et al. — J Orthop Res, 2014
2017

CNS and Neurological Tissue Research

Emerging research has investigated Tβ4 in spinal cord injury and traumatic brain injury models. Systemic Tβ4 administration in rat spinal cord contusion models showed improved locomotor recovery scores and reduced lesion volume at 5 weeks. Proposed neuroprotective mechanisms include oligodendrocyte preservation, reduced astrogliosis, and VEGF-mediated microvascular repair in the peri-lesion penumbra.

Morris DC et al. — J Neurosci Res, 2017

Reconstitution Reference

The following reference is provided for licensed research professionals only. All reconstitution and handling must comply with your institution's biosafety protocols.

Vial Size BAC Water Volume Resulting Concentration Storage Peptide Calculator
5 mg 2.0 mL 2,500 mcg/mL 2–8°C after reconstitution Calculate Dose →
10 mg 4.0 mL 2,500 mcg/mL 2–8°C after reconstitution Calculate Dose →

TB-500 lyophilised powder is stable at -20°C for up to 24 months when protected from moisture and light. Reconstituted solutions should be used within 28 days. Handle using aseptic technique under appropriate laboratory conditions.

Competitive Pricing Comparison

Market price data from independent competitor analysis. All products are For Research Use Only.

Supplier Price Range (per vial) Avg Market Price COA Available
Competitor Low $62 Varies
Competitor High $136 Varies
Market Average $92
Rainbow Peptide View Price → ✓ Yes — HPLC + MS

Research TB-500

View our TB-500 (Thymosin Beta-4) research compound specification, certificate of analysis, and current pricing for qualified research applications.

For Research Use Only. Not for human consumption.

Frequently Asked Questions

What is TB-500?

TB-500 is a synthetic peptide representing the active region of Thymosin Beta-4 (Tβ4), a ubiquitous 43 amino acid protein found in virtually all mammalian cells. TB-500 comprises the actin-binding domain of Tβ4 and is used in research models studying tissue repair, wound healing, and angiogenesis. All TB-500 is strictly For Research Use Only.

How does TB-500 differ from Thymosin Beta-4?

Thymosin Beta-4 is the full 43 amino acid endogenous protein. TB-500 is a synthetic fragment corresponding to the central actin-binding region (approximately residues 17-23), specifically the heptapeptide LKKTETQ. Research suggests this region retains much of the biological activity of the full protein in in vitro and animal model studies.

What is TB-500's primary mechanism of action?

TB-500's primary mechanism involves G-actin sequestration — binding to monomeric actin (G-actin) to regulate its availability for polymerisation. This controls actin cytoskeletal dynamics, cell migration, and remodelling. Additional mechanisms include downregulation of inflammatory cytokines and promotion of angiogenesis via integrin signalling.

How is TB-500 reconstituted for research?

A standard 5mg vial of TB-500 is reconstituted with 2mL bacteriostatic water to yield a concentration of 2,500 mcg/mL. Research protocols in animal studies typically explore doses in a broad range. Store reconstituted solutions at 2–8°C and use within 28 days.

Is TB-500 the same as Thymosin Beta-4?

TB-500 is a synthetic analogue representing the active actin-binding fragment of Thymosin Beta-4, not the full protein. In research contexts the terms are sometimes used interchangeably, but they are structurally distinct. All products from Rainbow Peptide are For Research Use Only.

Published Research References

Studies cited for scientific reference. All data from preclinical or in vitro models unless stated. Not medical advice.

  1. Goldstein AL, Kleinman HK. "Advances in the basic and clinical applications of thymosin β4." Expert Opin Biol Ther. 2015;15(S1):S139–145. PubMed 22909189 ↗
  2. Bock-Marquette I, et al. "Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432:466–472. PubMed 15290252 ↗
  3. Smart N, et al. "Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445:177–182. PubMed 17522624 ↗
  4. Huff T, et al. "Beta-thymosins, small acidic peptides with multiple functions." Int J Biochem Cell Biol. 2001;33(3):205–220. PubMed 11311852 ↗